Investigating the association between hidradenitis suppurativa and malignancy risks: a systematic review
Arch Dermatol Res
.
2024 Dec 5;317(1):68.
doi: 10.1007/s00403-024-03580-2.
Authors
Dea Metko
1
,
Shanti Mehta
2
,
Grace Xiong
3
,
Muskaan Sachdeva
4
,
Vincent Piguet
4
5
,
Jensen Yeung
4
6
5
Affiliations
1
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada. Dea.metko@medportal.ca.
2
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
3
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
4
Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
5
Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
6
Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
PMID:
39636420
DOI:
10.1007/s00403-024-03580-2
No abstract available
Keywords:
Adalimumab; Cancer; Hidradenitis Suppurativa; Inflammation; Malignancy.
Publication types
Letter